“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin Announces Appointment of New Independent Director
Mumbai, India, February 2, 2021: Lupin Limited (Lupin), global pharmaceutical company, announced the appointment of Mr. Mark D. McDade as an Independent Director effective January 28, 2021.
Mr. McDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led several high-value investments in biotherapeutics, including cell and gene therapy and digital health. With a career spanning over 37 years, he has led and transformed global companies as well as founded and advanced Biotech companies.
Commenting on the appointment, Manju D. Gupta, Chairman, Lupin said, “We are delighted to welcome Mr. Mark D. McDade on Lupin’s board. We are confident that his diverse experience across large, mid and development-stage companies across Specialty & Biologics, will help advance our growth journey.”
Mr. McDade holds a B.A. in History from Dartmouth College and MBA from Harvard Business School.
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/
For further information or queries please contact –
Head – Corporate Communications
Email: shwetamunjal@lupin.com
Head – Investor Relations / Corporate M&A
Email: arvindbothra@lupin.com
General Manager – Corporate Communications
Email: manjirasharma@lupin.com
